All In Biotech

Drug Trial Radar · NCT06419205

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Akebia TherapeuticsIndustry
Sponsor type
Industry
First posted
May 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)

Conditions

  • IgA Nephropathy
  • Lupus Nephritis (LN)
  • C3 (Complement Component 3) Glomerulopathy

Interventions

  • ADX-097Drug

    Subcutaneous Infusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants reporting treatment emergent adverse events (TEAEs)Time frame: Up to 30 weeks

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigator Site #3

    Hollywood, Florida · Recruiting

  • Investigator Site #1

    Lawrenceville, Georgia · Recruiting

  • Investigator Site #4

    Orangeburg, South Carolina · Recruiting

  • Investigator Site #2

    São Paulo, Brazil · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.